Polyrizon Signs Agreements with Three Clinical Sites for NASARIX™ Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 11 hours ago
0mins
Source: Newsfilter
- Clinical Network Expansion: Polyrizon Ltd. has signed agreements with two additional U.S. clinical sites, expanding its NASARIX™ study network to three major centers, which are expected to contribute the highest patient enrollment rates, thereby accelerating the clinical trial's progress.
- Study Design and Objectives: The upcoming multi-center clinical trial will evaluate the safety, tolerability, and efficacy of the NASARIX™ Allergy Blocker in patients with seasonal allergic rhinitis, adhering to international Good Clinical Practice standards to ensure scientific rigor and compliance.
- Efficient Recruitment Advantage: CEO Tomer Izraeli stated that securing three leading clinical centers early will facilitate efficient patient recruitment and timely study execution, demonstrating the company's strong capability in executing its clinical plans.
- Innovative Product Development: NASARIX™ is an intranasal hydrogel formulation designed to create a protective barrier in the nasal cavity to block airborne allergens, potentially offering a non-pharmacological approach to allergy prevention and opening new therapeutic options in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PLRZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PLRZ
About PLRZ
Polyrizon Ltd is an Israel-based biotechnology company. The Company is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The Company is focused not only on the development of intranasal products, but also on commercialization. The Company cooperates with medical specialists and researchers..
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Polyrizon Signs Agreements with Three Clinical Sites for NASARIX™ Study
- Clinical Network Expansion: Polyrizon Ltd. has signed agreements with two additional U.S. clinical sites, expanding its NASARIX™ study network to three major centers, which are expected to contribute the highest patient enrollment rates, thereby accelerating the clinical trial's progress.
- Study Design and Objectives: The upcoming multi-center clinical trial will evaluate the safety, tolerability, and efficacy of the NASARIX™ Allergy Blocker in patients with seasonal allergic rhinitis, adhering to international Good Clinical Practice standards to ensure scientific rigor and compliance.
- Efficient Recruitment Advantage: CEO Tomer Izraeli stated that securing three leading clinical centers early will facilitate efficient patient recruitment and timely study execution, demonstrating the company's strong capability in executing its clinical plans.
- Innovative Product Development: NASARIX™ is an intranasal hydrogel formulation designed to create a protective barrier in the nasal cavity to block airborne allergens, potentially offering a non-pharmacological approach to allergy prevention and opening new therapeutic options in the market.
See More
Biotech Stocks Surge with Akari Leading the Rally
- Akari Therapeutics Surge: Akari Therapeutics (AKTX) soared over 255% on Friday, marking its second consecutive day of gains following the announcement of breakthrough preclinical data for its drug AKTX-101, which demonstrated synergistic effects in KRAS-mutated pancreatic cancer models, highlighting significant advancements in oncology.
- MetaVia Clinical Progress: MetaVia Inc. (MTVA) rose over 34% on Friday as the company advances its DA-1726 in a Phase 1 trial for treating cardiometabolic diseases, with an end-of-Phase 2 meeting with the FDA planned, indicating strong potential in the cardiometabolic sector.
- GeoVax Vaccine Development: GeoVax Labs Inc. (GOVX) increased over 32% on Friday amid a growing Ebola outbreak, as the company progresses its vaccine development against Ebola and Marburg viruses, with a pivotal Phase 3 study of its GEO-MVA candidate set to begin in Q4 2026, underscoring its role in addressing public health emergencies.
- Polyrizon Clinical Agreement: Polyrizon Ltd. (PLRZ) gained over 20% on Friday after signing its first Clinical Trial Agreement for NASARIX Allergy Blocker, aimed at treating seasonal allergic rhinitis, marking a significant step towards initiating its first-in-human clinical study and showcasing its innovative potential in biotechnology.
See More
Polyrizon Signs Clinical Trial Agreement for NASARIX Allergy Blocker
- Clinical Trial Agreement Signed: Polyrizon Ltd. has signed its first Clinical Trial Agreement with a Texas-based clinical research site, marking a significant milestone in advancing its NASARIXTM Allergy Blocker from development to potential clinical validation.
- Multi-Center Study Plan: The clinical study will evaluate the safety, tolerability, and efficacy of NASARIXTM in patients with seasonal allergic rhinitis, with plans to add additional clinical sites to broaden the study's scope.
- Non-Pharmacological Innovation: NASARIXTM is an investigational intranasal formulation designed to create a protective barrier against airborne allergens, showcasing Polyrizon's innovative potential in the biomedical device sector.
- Compliance with International Standards: The trial will be conducted in accordance with international Good Clinical Practice (GCP) standards and applicable regulatory requirements, supporting Polyrizon's broader regulatory strategy to ensure compliance and effectiveness of the research.
See More
Polyrizon Advances Biophysical Barrier Technology Amid Respiratory Threats
- Technological Innovation: Polyrizon's Capture&Contain™ platform utilizes proprietary polysaccharide formulations to rapidly form a protective biophysical layer on the nasal mucosa, addressing emerging respiratory virus threats, particularly in the early stages before vaccines and therapeutics are developed.
- Laboratory Study Results: Controlled in-vitro studies demonstrate that this technology can effectively limit viral-host interactions across multiple respiratory virus families, such as influenza and coronaviruses, with treated cell cultures showing better cell viability, supporting its potential effectiveness.
- Market Demand: As the world faces increasingly frequent viral outbreaks, Polyrizon's technology is viewed as a fast, adaptable non-specific protection measure that could become a strategic asset for governments and healthcare systems in enhancing resilience against future threats.
- Investment Opportunity: Although the Capture&Contain™ platform is still in pre-clinical stages, its differentiated opportunity in pandemic preparedness and respiratory protection may present an attractive market prospect for investors.
See More
Polyrizon Advances Biophysical Barrier Technology for Respiratory Defense
- Technological Innovation: Polyrizon is advancing its Capture&Contain™ platform, which utilizes proprietary polysaccharide formulations to create a protective biophysical layer on the nasal mucosa, aimed at addressing emerging respiratory virus threats, particularly Hantavirus and novel coronavirus variants.
- Market Demand: With the rise of Hantavirus cluster cases, there is an increasing global need for broad-spectrum protective solutions, and Polyrizon's technology can provide immediate defense before pathogen-specific vaccines and therapeutics are developed, thereby reducing public health risks.
- Laboratory Validation: Laboratory studies conducted under controlled in-vitro conditions demonstrate that this technology can effectively limit viral-host interactions across multiple respiratory virus families, with treated cell cultures showing better preservation of cell viability, supporting its potential effectiveness.
- Strategic Positioning: Polyrizon's PL-16 product candidate, based on the Capture&Contain™ technology, while still in pre-clinical stages, may represent a differentiated opportunity in the rapidly growing field of pandemic preparedness and respiratory protection, aligning with the global demand for fast, adaptable protective technologies.
See More
Polyrizon Files New Patent to Enhance Drug Delivery
- Patent Application Progress: Polyrizon has filed a divisional patent application with the European Patent Office for its Trap & Target (T&T) platform, aimed at protecting its advanced intranasal drug delivery system, thereby enhancing drug efficacy and prolonging residence time in the nasal cavity.
- Technological Innovation: The T&T platform addresses critical challenges in local and systemic drug delivery by improving the bioavailability of active pharmaceutical ingredients, which is expected to significantly enhance respiratory health and drug delivery effectiveness.
- Market Potential: The platform's design includes features such as prolonged residence time, improved bioavailability, and controlled release, making it suitable for a wide range of drug types and offering extensive therapeutic application potential.
- Strategic Significance: CEO Tomer Izraeli emphasized that this patent application marks an important step in strengthening the global intellectual property portfolio, demonstrating the company's commitment to addressing healthcare challenges through innovative technology and improving patient outcomes.
See More
Polyrizon Signs Agreements with Three Clinical Sites for NASARIX™ Study
- Clinical Network Expansion: Polyrizon Ltd. has signed agreements with two additional U.S. clinical sites, expanding its NASARIX™ study network to three major centers, which are expected to contribute the highest patient enrollment rates, thereby accelerating the clinical trial's progress.
- Study Design and Objectives: The upcoming multi-center clinical trial will evaluate the safety, tolerability, and efficacy of the NASARIX™ Allergy Blocker in patients with seasonal allergic rhinitis, adhering to international Good Clinical Practice standards to ensure scientific rigor and compliance.
- Efficient Recruitment Advantage: CEO Tomer Izraeli stated that securing three leading clinical centers early will facilitate efficient patient recruitment and timely study execution, demonstrating the company's strong capability in executing its clinical plans.
- Innovative Product Development: NASARIX™ is an intranasal hydrogel formulation designed to create a protective barrier in the nasal cavity to block airborne allergens, potentially offering a non-pharmacological approach to allergy prevention and opening new therapeutic options in the market.
See More
Biotech Stocks Surge with Akari Leading the Rally
- Akari Therapeutics Surge: Akari Therapeutics (AKTX) soared over 255% on Friday, marking its second consecutive day of gains following the announcement of breakthrough preclinical data for its drug AKTX-101, which demonstrated synergistic effects in KRAS-mutated pancreatic cancer models, highlighting significant advancements in oncology.
- MetaVia Clinical Progress: MetaVia Inc. (MTVA) rose over 34% on Friday as the company advances its DA-1726 in a Phase 1 trial for treating cardiometabolic diseases, with an end-of-Phase 2 meeting with the FDA planned, indicating strong potential in the cardiometabolic sector.
- GeoVax Vaccine Development: GeoVax Labs Inc. (GOVX) increased over 32% on Friday amid a growing Ebola outbreak, as the company progresses its vaccine development against Ebola and Marburg viruses, with a pivotal Phase 3 study of its GEO-MVA candidate set to begin in Q4 2026, underscoring its role in addressing public health emergencies.
- Polyrizon Clinical Agreement: Polyrizon Ltd. (PLRZ) gained over 20% on Friday after signing its first Clinical Trial Agreement for NASARIX Allergy Blocker, aimed at treating seasonal allergic rhinitis, marking a significant step towards initiating its first-in-human clinical study and showcasing its innovative potential in biotechnology.
See More
Polyrizon Signs Clinical Trial Agreement for NASARIX Allergy Blocker
- Clinical Trial Agreement Signed: Polyrizon Ltd. has signed its first Clinical Trial Agreement with a Texas-based clinical research site, marking a significant milestone in advancing its NASARIXTM Allergy Blocker from development to potential clinical validation.
- Multi-Center Study Plan: The clinical study will evaluate the safety, tolerability, and efficacy of NASARIXTM in patients with seasonal allergic rhinitis, with plans to add additional clinical sites to broaden the study's scope.
- Non-Pharmacological Innovation: NASARIXTM is an investigational intranasal formulation designed to create a protective barrier against airborne allergens, showcasing Polyrizon's innovative potential in the biomedical device sector.
- Compliance with International Standards: The trial will be conducted in accordance with international Good Clinical Practice (GCP) standards and applicable regulatory requirements, supporting Polyrizon's broader regulatory strategy to ensure compliance and effectiveness of the research.
See More
Polyrizon Advances Biophysical Barrier Technology Amid Respiratory Threats
- Technological Innovation: Polyrizon's Capture&Contain™ platform utilizes proprietary polysaccharide formulations to rapidly form a protective biophysical layer on the nasal mucosa, addressing emerging respiratory virus threats, particularly in the early stages before vaccines and therapeutics are developed.
- Laboratory Study Results: Controlled in-vitro studies demonstrate that this technology can effectively limit viral-host interactions across multiple respiratory virus families, such as influenza and coronaviruses, with treated cell cultures showing better cell viability, supporting its potential effectiveness.
- Market Demand: As the world faces increasingly frequent viral outbreaks, Polyrizon's technology is viewed as a fast, adaptable non-specific protection measure that could become a strategic asset for governments and healthcare systems in enhancing resilience against future threats.
- Investment Opportunity: Although the Capture&Contain™ platform is still in pre-clinical stages, its differentiated opportunity in pandemic preparedness and respiratory protection may present an attractive market prospect for investors.
See More
Polyrizon Advances Biophysical Barrier Technology for Respiratory Defense
- Technological Innovation: Polyrizon is advancing its Capture&Contain™ platform, which utilizes proprietary polysaccharide formulations to create a protective biophysical layer on the nasal mucosa, aimed at addressing emerging respiratory virus threats, particularly Hantavirus and novel coronavirus variants.
- Market Demand: With the rise of Hantavirus cluster cases, there is an increasing global need for broad-spectrum protective solutions, and Polyrizon's technology can provide immediate defense before pathogen-specific vaccines and therapeutics are developed, thereby reducing public health risks.
- Laboratory Validation: Laboratory studies conducted under controlled in-vitro conditions demonstrate that this technology can effectively limit viral-host interactions across multiple respiratory virus families, with treated cell cultures showing better preservation of cell viability, supporting its potential effectiveness.
- Strategic Positioning: Polyrizon's PL-16 product candidate, based on the Capture&Contain™ technology, while still in pre-clinical stages, may represent a differentiated opportunity in the rapidly growing field of pandemic preparedness and respiratory protection, aligning with the global demand for fast, adaptable protective technologies.
See More
Polyrizon Files New Patent to Enhance Drug Delivery
- Patent Application Progress: Polyrizon has filed a divisional patent application with the European Patent Office for its Trap & Target (T&T) platform, aimed at protecting its advanced intranasal drug delivery system, thereby enhancing drug efficacy and prolonging residence time in the nasal cavity.
- Technological Innovation: The T&T platform addresses critical challenges in local and systemic drug delivery by improving the bioavailability of active pharmaceutical ingredients, which is expected to significantly enhance respiratory health and drug delivery effectiveness.
- Market Potential: The platform's design includes features such as prolonged residence time, improved bioavailability, and controlled release, making it suitable for a wide range of drug types and offering extensive therapeutic application potential.
- Strategic Significance: CEO Tomer Izraeli emphasized that this patent application marks an important step in strengthening the global intellectual property portfolio, demonstrating the company's commitment to addressing healthcare challenges through innovative technology and improving patient outcomes.
See More
